Who knows really. It really becomes undeniable that the drug works if there's strong results in 3 indications in 3 different trails across 2 different countries.
The Q2 result wasn't what I expected, nor was it good, but it wasn't a disaster. Market will assume a further downgrade may occur but the commentary around the retention and patient adds is good. ACAD mentioned they had seen a positive change in net patient starts which was true, it just wasn't enough to maintain the guidance. 2 quarters of negative sales growth would be a disaster IMO.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$14.20 |
Change
0.890(6.69%) |
Mkt cap ! $1.761B | |||
| Open | High | Low | Value | Volume |
| $13.50 | $14.26 | $12.96 | $9.111M | 655.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2000 | $14.17 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.23 | 3278 | 1 |
View Market Depth
| Last trade - 16.15pm 27/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |